NEWS

BeeKeeperAI Raises $12.1 Million Series A to Accelerate AI Development on Privacy Protected Healthcare Data
BeeKeeperAI Raises $12.1 Million Series A to Accelerate AI Development on Privacy Protected Healthcare Data 06/29/2023
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma 06/23/2023
MindRhythm Announces First Patient Enrolled in Pivotal Study of Novel Harmony™ Device for Rapid Detection of Stroke
MindRhythm Announces First Patient Enrolled in Pivotal Study of Novel Harmony™ Device for Rapid Detection of Stroke 06/22/2023
Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis
Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis 06/20/2023
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epileps
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epileps 06/20/2023
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting 06/07/2023
Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection
Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection 06/04/2023
UCSF NewCo Vevo Therapeutics has been Selected to Join the AWS Startups Generative AI Accelerator
UCSF NewCo Vevo Therapeutics has been Selected to Join the AWS Startups Generative AI Accelerator 05/31/2023
Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023
Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023 05/30/2023
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial 04/25/2023
Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Exai Bio Presents New Non-Small Cell Lung Cancer Early Detection Data at the American Association for Cancer Research (AACR) 2023 Annual Meeting 04/19/2023
Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases
Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases 04/14/2023
The First FDA-Approved Video Game Was Developed in San Francisco
The First FDA-Approved Video Game Was Developed in San Francisco 04/10/2023
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Therapies for Autoimmune Diseases
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Therapies for Autoimmune Diseases 04/03/2023
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai’s Novel RNA-based Liquid Biopsy Platform in Breast Cancer 03/30/2023